博雅生物(300294) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥654,635,799.08, a decrease of 4.89% compared to the adjusted revenue of ¥672,101,665.87 in the same period last year[5] - Net profit attributable to shareholders for Q1 2022 was ¥103,554,147.18, representing a 2.80% increase from the adjusted net profit of ¥100,736,164.66 in the previous year[5] - Basic and diluted earnings per share for Q1 2022 were both ¥0.21, down 12.50% from ¥0.24 in the previous year[5] - Total operating revenue for the current period reached ¥654,635,799.08, an increase of 4.1% compared to ¥624,118,627.05 in the previous period[35] - Net profit for the current period was ¥106,852,356.15, compared to ¥103,957,040.08 in the previous period, marking an increase of 2.8%[38] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 86.10%, amounting to ¥22,146,972.56 compared to ¥159,306,575.70 in the same period last year[5] - The company reported a net cash flow from investing activities of -712,158,654.56, compared to -23,839,711.56 in the previous period, indicating a significant increase in investment outflows[46] - The net increase in cash and cash equivalents was -690,691,299.91, compared to -78,882,618.94 in the previous period, showing a substantial decline in cash reserves[46] - The ending balance of cash and cash equivalents was 888,570,197.44, down from 1,579,261,497.35 at the beginning of the period[46] - Cash paid for dividends and interest decreased by 98.37% due to reduced interest expenses[14] Assets and Liabilities - The total assets at the end of Q1 2022 were ¥7,679,391,433.49, reflecting a 0.76% increase from ¥7,621,775,902.48 at the end of the previous year[5] - The total liabilities of the company were RMB 652,063,023.89, down from RMB 701,299,849.03, showing a reduction in liabilities[31] - The company's non-current assets totaled RMB 1,959,146,016.98, a decrease from RMB 1,975,862,937.59[31] - Accounts receivable decreased by 100% due to the cancellation of commercial acceptance settlements in 2022 and the maturity of commercial acceptances in 2021[14] Investments and Expenditures - The company plans to invest RMB 996,075,100.00 in the construction of a blood product intelligent factory, reallocating unused funds from a previous project[24] - Cash paid for purchasing goods and receiving services increased by 57.02% primarily due to increased procurement[14] - Cash paid for investment increased by 726.54% mainly due to the purchase of financial products[14] - The company made significant investments totaling 700,000,000.00, indicating a focus on growth and expansion[46] Changes in Equity and Financial Management - The equity attributable to shareholders increased by 1.52% to ¥6,932,628,390.75 from ¥6,829,074,243.57 at the end of the previous year[5] - The weighted average return on equity decreased by 0.92 percentage points to 1.50% from 2.42% in the previous year[5] - The company recorded a financial expense of -¥6,202,545.54, compared to -¥784,174.50 in the previous period, indicating improved financial management[35] Operational Adjustments and Strategic Focus - The company has made adjustments to its accounting policies, affecting revenue recognition for certain cooperative production agreements[8] - The company is focusing on expanding its market presence through the development of new products and technologies[24] - The company is focusing on strategic investments and may be exploring new technologies and market expansions based on the significant cash outflows for investments[46] Other Financial Metrics - Research and development expenses were ¥6,870,470.10, down from ¥8,165,544.65, reflecting a decrease of 15.8%[35] - Other income for the current period was ¥1,702,903.79, up from ¥1,081,046.33, representing an increase of 57.5%[38] - The report for the first quarter was not audited, which may affect the reliability of the financial data presented[47]